Heron Therapeutics (HRTX) Asset Writedowns and Impairment (2019 - 2026)

Heron Therapeutics (HRTX) has 8 years of Asset Writedowns and Impairment data on file, last reported at $7000.0 in Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152000.0 (down 96.41% YoY) and the FY2025 annual result came in at $414000.0, down 90.61% from the prior year.
• Asset Writedowns and Impairment climbed to $7000.0 in Q1 2026, from $5000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $3.3 million in Q2 2024 to a low of $5000.0 in Q4 2025.
• A 5-year average of $374785.7 and a median of $147000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment surged 2010.32% — and 2025, when it sank 96.43%.
• Tracing HRTX's Asset Writedowns and Impairment over 5 years: stood at $79000.0 in 2022, then surged by 94.94% to $154000.0 in 2023, then dropped by 9.09% to $140000.0 in 2024, then slumped by 96.43% to $5000.0 in 2025, then jumped by 40.0% to $7000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $7000.0 (Q1 2026), $5000.0 (Q4 2025), and $140000.0 (Q4 2024), per Business Quant data.